| Objective: The purpose of this study is to observe the effects of Jiaweisinisan clinical efficacy of the treatment of non erosive reflux disease in liver and stomach,to further explore the mechanism of Jiaweisinisan treatment of this disease. The clinical study for the treatment of NERD(Disharmony between Liver and Stomach)to explore new methods.Methods:(1) All cases of this study come from the clinic of spleen and stomach diseases from October 2014 to December 2015, which hospital named Affiliated Hospital of Shanxi University of Traditional C hinese Medicine. The study uses the random contrast method, selected 60 patients included in the standard of traditional C hinese medicine and Western Medicine. Sixty patients were divided treatment group(30 cases)and control gro up(30 cases).(2) The treatment group is treated by Jiaweisinisan, one dose per day; the control group is given mosapride capsule, 5mg tid p.o. Two groups of patients referral once a week, totally four weeks of treatment. Before the treatment and after the treatment two groups of patients complete RDQ questionnaires?TCM Symptoms Scale?Esophageal pressure determination, the statistical analysis of all data, by observing the two groups before and after treatment were integral, to evaluate the curative effect.(3) All data were statistical analyzed by SPSS18.0 statistical software.Results: 1. The improvement of clinical symptoms(1) The treatment group and the control group improve the RDQ score total efficiency are 83.33% and 70.00%, differences between the two groups were significant(P<0.05).(2) Comparing the two groups RDQ integral before and after treatment, difference was statistically significant(P<0.05);comparing the two groups RDQ integral after treatment, difference was statistically significant(P<0.05).(3)Intra- group comparison: all single integral had significant difference in the treatment group(P<0.05);the heartburn, acid regurgitation, reflux symptoms had statistical sense in the control group(P<0.05);results of all single integral significant difference between the two groups after treatment(P<0.05).(4)After treatment the treatment group and the control group improve the TCM comprehensive syndrome efficiency respectively was 86.66% and 73.33%, difference was statistically significant(P<0.05).(5)Intra- group comparison: all single TCM integral had significant difference in the treatment group(P<0.05);it was found that the control group in the improvement of reflux, heartburn, belching, loss of appetite, nausea has statistical significance(P<0.05), there was no statistical significance difference in chest pain and symptoms exacerbate when patients out of sorts(P>0.05). All the integral were compared between the two groups after treatment, it was found that the treatment group in the improvement of reflux, heartburn, chest pain, belching, symptoms exacerbate when patients out of sorts has statistical significance(P<0.05);the loss of appetite, nausea were no statistical significance(P>0.05). 2.Esophageal motility improvement:(1)After treatment, the treatment group and the control group LESP had different degrees of increase compared with before treatment: 23.85±3.16 mm Hg vs12.24±5.86 mm Hg; 17.69±5.18 mm Hg vs11.85±6.38 mm Hg, difference was statistically significant(P<0.05). The treatment group was significantly higher than the control group about LESP(P<0.05).(2)After treatment, the treatment group and the control group PA increased compared with that before the treatment was: 72.70±28.76 mm Hg vs 54.39±24.13 mm Hg, difference were statistically significant(P<0.05);64.89±25.17 mm Hg vs57.82±22.33 mm Hg, difference was statistically significant(P<0.05), the treatment group was significantly higher than the control group about PA(P<0.05).(3)After treatment, the success rate of wet swallowing increased in varying degrees of the treatment group and the control group, there was:72.53±23.62% vs 47.50±26.13%;69.71±36.04% vs 46.50±32.61%, difference was statistically significant(P<0.05),the difference between the two groups was not statistically significant(P>0.05).(4)After treatment, the treatment group and the control group DCI had different degrees of increase compared with before treatment : 974.30±428.81 mm Hg.cm.s vs 732.08±191.60 mm Hg.cm.s; 936.21±331.28 mm Hg.cm.s vs 694.23±178.36 mm Hg.cm.s, difference was statistically significant(P<0.05), the difference between the two groups was not statistically significant(P>0.05). 3. Before and after treatment in the two groups were no obvious adverse reaction.Conclusions: 1. The RDQ integral of two groups significantly improve, the total efficiency of Jiaweisinisan group was 83.33%,the total efficiency of Mosapride C itrate group was 70.00%, the result showed that Jiaweisinisan in the improvement of RDQ integral was better than the Mosapride C itrate group. It can be seen by the RDQ single integral, it was found that the Jiaweisinisan group in the improvement of heartburn, chest pain, reflux, acid regurgitation was better than the Mosapride C itrate group. 2. The total effective rate of the TCM syndrome of treatment group or control group was86.66% and 73.33%,the total effective rate of the treatment group was better than the control group. 3. The Jiaweisinisan can improve significantly the heartburn, chest pain, acid regurgitation, belching, symptoms exacerbate when patients out of sorts, such as those symptoms of Disharmony between Liver and Stomach. It means Jiaweisinisan could obviously improve symptoms of patients with NERD( Disharmony between Liver and Stomach). 4. Two groups all can improve the LESP, PA, the success rate of wet swallowing, DCI of patients with NERD, but Jiaweisinisan is better than the control group in improving patients LESP and PA. It shows that patients with NERD may have esophageal motility disorder, Jiaweisinisan can improve the LESP, esophageal motility disorders, strengthen esophageal motility effectively, and it can prevent reflux, improve gastro-esophageal reflux symptoms of patients. 5. There were no abnormal symptoms with patients' blood routine, urinalysis, stool routine, liver function and kidney function before and after the treatment, and no gastrointestinal allergic reaction. The above means Jiaweisinisan is safe in clinical application. |
PDF Full Text Request